Literature DB >> 12839708

Therapy of cutaneous leishmaniasis.

Samuel A Lee1, Rodrigo Hasbun.   

Abstract

There have been many treatment modalities used for the therapy of cutaneous leishmaniasis. Although treatment need not be given for cosmetically insignificant lesions, which are often self-limited, therapy is usually indicated for larger, cosmetically significant and disfiguring lesions, and lesions which progress. This review summarizes the published evidence in support of the numerous therapeutic options that have been employed for cutaneous leishmaniasis.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12839708     DOI： 10.1016/s1201-9712(03)90002-6

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN： 1201-9712            Impact factor:   3.623


  8 in total

1.  [Topical treatment of persistent cutaneous leishmaniasis with paromomycin].

Authors:  M J Flaig; J Rupec; T Ruzicka; R A Rupec
Journal:  Hautarzt       Date:  2007-08       Impact factor: 0.751

2.  [Cutaneous leishmaniasis].

Authors:  E von Stebut; C Sunderkötter
Journal:  Hautarzt       Date:  2007-05       Impact factor: 0.751

3.  Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis.

Authors:  Daniela R Faria; Kenneth J Gollob; José Barbosa; Albert Schriefer; Paulo R L Machado; Hélio Lessa; Lucas P Carvalho; Marco Aurélio Romano-Silva; Amélia R de Jesus; Edgar M Carvalho; Walderez O Dutra
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Old World cutaneous leishmaniasis: diagnosis and treatment.

Authors:  Abderrahmen Masmoudi; Wala Hariz; Slaheddine Marrekchi; Mariem Amouri; Hamida Turki
Journal:  J Dermatol Case Rep       Date:  2013-06-30

5.  Recruitment of CD8(+) T cells expressing granzyme A is associated with lesion progression in human cutaneous leishmaniasis.

Authors:  D R Faria; P E A Souza; F V Durães; E M Carvalho; K J Gollob; P R Machado; W O Dutra
Journal:  Parasite Immunol       Date:  2009-08       Impact factor: 2.280

6.  Comparison between Combination Therapy of Oral Terbinafine and Cryotherapy versus Systemic Meglumine Antimoniate and Cryotherapy in Cutaneous Leishmaniasis: A Randomized Clinical Trial.

Authors:  Saeedeh Farajzadeh; Iraj Esfandiarpour; Ali Akbar Haghdoost; Saman Mohammadi; Azadeh Mohebbi; Elham Mohebbi; Mahshid Mostafavi
Journal:  Iran J Parasitol       Date:  2015 Jan-Mar       Impact factor: 1.012

Review 7.  Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis.

Authors:  Diana Caridha; Brian Vesely; Katrien van Bocxlaer; Byron Arana; Charles E Mowbray; Sima Rafati; Silvia Uliana; Rosa Reguera; Mara Kreishman-Deitrick; Richard Sciotti; Pierre Buffet; Simon L Croft
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-06-20       Impact factor: 4.077

8.  A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia.

Authors:  Liliana López; Iván Vélez; Claudia Asela; Claudia Cruz; Fabiana Alves; Sara Robledo; Byron Arana
Journal:  PLoS Negl Trop Dis       Date:  2018-07-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.